| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $49,957 | 1 | 1 |
Sells | $654,252,666 | 66 | 99 |
| Gline Matthew | CEO | 1 | $49,957 | 1 | $37.72M | $-37.67M |
| Pulik Richard | CFO | 0 | $0 | 1 | $9.12M | $-9.12M |
| Sukhatme Mayukh | President & CIO | 0 | $0 | 4 | $38.51M | $-38.51M |
| Venker Eric | President & COO | 0 | $0 | 26 | $97.6M | $-97.6M |
| MANCHESTER KEITH S | director | 0 | $0 | 6 | $98.03M | $-98.03M |
| QVT Financial LP | Director by Deputization | 0 | $0 | 6 | $98.03M | $-98.03M |
| Gold Daniel Allen | director | 0 | $0 | 7 | $115.24M | $-115.24M |
| Ramaswamy Vivek | 10 percent owner | 0 | $0 | 15 | $160.01M | $-160.01M |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Over the last 12 months, insiders at Roivant Sciences Ltd. have bought $49,957 and sold $654.25M worth of Roivant Sciences Ltd. stock.
On average, over the past 5 years, insiders at Roivant Sciences Ltd. have bought $20.16M and sold $567.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gline Matthew (CEO) — $49,957.
The last purchase of 3,315 shares for transaction amount of $49,957 was made by Gline Matthew (CEO) on 2025‑09‑18.
| 2026-02-13 | Sale | QVT Financial LP | Director by Deputization | 375,784 0.0526% | $26.50 | $9.96M | +2.06% | |
| 2026-02-13 | Sale | MANCHESTER KEITH S | director | 375,784 0.0526% | $26.50 | $9.96M | +2.06% | |
| 2026-02-13 | Sale | Gold Daniel Allen | director | 375,784 0.0526% | $26.50 | $9.96M | +2.06% | |
| 2026-02-12 | Sale | QVT Financial LP | Director by Deputization | 425,000 0.0594% | $26.75 | $11.37M | -0.99% | |
| 2026-02-12 | Sale | MANCHESTER KEITH S | director | 425,000 0.0594% | $26.75 | $11.37M | -0.99% | |
| 2026-02-12 | Sale | Gold Daniel Allen | director | 425,000 0.0594% | $26.75 | $11.37M | -0.99% | |
| 2026-02-11 | Sale | QVT Financial LP | Director by Deputization | 425,000 0.0591% | $26.67 | $11.33M | +1.53% | |
| 2026-02-11 | Sale | MANCHESTER KEITH S | director | 425,000 0.0591% | $26.67 | $11.33M | +1.53% | |
| 2026-02-11 | Sale | Gold Daniel Allen | director | 425,000 0.0591% | $26.67 | $11.33M | +1.53% | |
| 2026-02-09 | Sale | Sukhatme Mayukh | President & CIO | 339,441 0.0467% | $26.47 | $8.99M | -2.69% | |
| 2026-01-12 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0284% | $21.92 | $4.38M | +3.70% | |
| 2025-12-31 | Sale | Sukhatme Mayukh | President & CIO | 1.02M 0.1471% | $21.71 | $22.12M | +4.68% | |
| 2025-12-29 | Sale | Sukhatme Mayukh | President & CIO | 311,873 0.0439% | $21.74 | $6.78M | +4.06% | |
| 2025-12-24 | Sale | Venker Eric | President & Immunovant CEO | 75,000 0.0108% | $22.53 | $1.69M | -1.20% | |
| 2025-12-23 | Sale | Venker Eric | President & Immunovant CEO | 200,000 0.0285% | $22.45 | $4.49M | -0.38% | |
| 2025-12-23 | Sale | Pulik Richard | CFO | 406,731 0.0578% | $22.43 | $9.12M | -0.38% | |
| 2025-12-17 | Sale | Sukhatme Mayukh | President & CIO | 26,831 0.0039% | $23.09 | $619,528 | -1.19% | |
| 2025-12-17 | Sale | QVT Financial LP | Director by Deputization | 777,332 0.1136% | $23.07 | $17.94M | -1.19% | |
| 2025-12-17 | Sale | MANCHESTER KEITH S | director | 777,332 0.1136% | $23.07 | $17.94M | -1.19% | |
| 2025-12-17 | Sale | Gold Daniel Allen | director | 777,332 0.1136% | $23.07 | $17.94M | -1.19% |
| Ramaswamy Vivek | 10 percent owner | 34132463 4.7691% | $924.48M | 0 | 18 | |
| Sukhatme Mayukh | President & CIO | 19148664 2.6755% | $518.64M | 0 | 7 | |
| Gline Matthew | CEO | 17290820 2.4159% | $468.32M | 1 | 13 | |
| MANCHESTER KEITH S | director | 15127329 2.1136% | $409.72M | 0 | 11 | |
| QVT Financial LP | Director by Deputization | 15127329 2.1136% | $409.72M | 0 | 13 | |
| Gold Daniel Allen | director | 15127329 2.1136% | $409.72M | 0 | 13 | |
| Venker Eric | President & Immunovant CEO | 1654597 0.2312% | $44.81M | 0 | 85 | |
| Pulik Richard | CFO | 239413 0.0335% | $6.48M | 0 | 3 | |
| Dexcel Pharma Technologies Ltd. | director | 102849443 14.3704% | $2.79B | 3 | 0 | +38.64% |
| Oren Dan | 98840843 13.8104% | $2.68B | 1 | 0 | +22.38% | |
| SVF Investments (UK) Ltd | 10 percent owner | 73031667 10.2042% | $1.98B | 0 | 3 | |
| Sumitomo Chemical Co., Ltd. | 10 percent owner | 71251083 9.9554% | $1.93B | 0 | 1 | |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 641010 0.0896% | $17.36M | 0 | 1 | |
| VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 641010 0.0896% | $17.36M | 0 | 1 | |
| Kumar Rakhi | Chief Accounting Officer | 163264 0.0228% | $4.42M | 0 | 23 |
$961,890,236 | 276 | 22.46% | $20.13B | |
$211,610,344 | 91 | 38.45% | $11.07B | |
$2,765,836 | 72 | 20.00% | $11.52B | |
$108,876,545 | 67 | 72.81% | $9.46B | |
$2,449,191,716 | 58 | 16.50% | $82.45B | |
$11,789,714 | 49 | 14.35% | $32.1B | |
$323,530,732 | 48 | 29.90% | $44.11B | |
$88,307,390 | 38 | -1.70% | $10.21B | |
$19,233,721 | 36 | 70.14% | $11.82B | |
$13,655,378 | 35 | 17.13% | $21.82B | |
$15,836,193 | 25 | 17.98% | $121.26B | |
$415,090,639 | 19 | -14.04% | $14.62B | |
$143,065,458 | 17 | 8.01% | $19.45B | |
$152,272,932 | 16 | -10.78% | $19.45B | |
$627,701,115 | 15 | 145.68% | $11.67B | |
$284,820 | 10 | 45.67% | $13.18B | |
Roivant Sciences Ltd. (ROIV) | $40,276,273 | 4 | 34.57% | $19.38B |
$36,900,000 | 3 | -9.12% | $11.26B | |
$999,989 | 1 | 262.16% | $17.16B |
| Increased Positions | 263 | +84.03% | 107M | +20.7% |
| Decreased Positions | 134 | -42.81% | 83M | -16.11% |
| New Positions | 107 | New | 17M | New |
| Sold Out Positions | 45 | Sold Out | 13M | Sold Out |
| Total Postitions | 442 | +41.21% | 541M | +4.59% |
| Fmr Llc | $1.33M | 8.74% | 60.77M | +5M | +9.47% | 2025-09-30 |
| Morgan Stanley | $972,000.00 | 6.38% | 44.32M | -371,109 | -0.83% | 2025-09-30 |
| Sb Investment Advisers (Uk) Ltd | $884,111.00 | 5.8% | 40.32M | -20M | -32.76% | 2025-09-30 |
| Blackrock, Inc. | $871,167.00 | 5.72% | 39.72M | -591,428 | -1.47% | 2025-09-30 |
| Vanguard Group Inc | $850,992.00 | 5.58% | 38.8M | -521,408 | -1.33% | 2025-09-30 |
| Qvt Financial Lp | $644,339.00 | 4.23% | 29.38M | 0 | 0% | 2025-09-30 |
| Viking Global Investors Lp | $517,435.00 | 3.4% | 23.59M | -11M | -31.09% | 2025-09-30 |
| Rubric Capital Management Lp | $438,600.00 | 2.88% | 20M | -370,336 | -1.82% | 2025-09-30 |
| State Street Corp | $410,094.00 | 2.69% | 18.7M | -1M | -5.43% | 2025-09-30 |
| Patient Square Capital Lp | $273,686.00 | 1.8% | 12.48M | 0 | 0% | 2025-09-30 |